<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Sarepta Therapeutics - Patent Portfolio | DMD Exon 44 Analysis</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap" rel="stylesheet">
    <style>
        * { font-family: 'Inter', sans-serif; }
        .tab-content { display: none; }
        .tab-content.active { display: block; }
        .tab-button.active { 
            border-bottom-color: rgb(99 102 241); 
            color: rgb(99 102 241);
        }
    </style>
</head>
<body class="bg-gray-50 text-gray-900">
    <!-- Header -->
    <header class="bg-white border-b border-gray-200">
        <div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8 py-6">
            <div class="flex items-center justify-between">
                <div>
                    <h1 class="text-3xl font-bold text-gray-900">Sarepta Therapeutics</h1>
                    <p class="text-lg text-gray-600 mt-1">Patent Portfolio - IP Risk Assessment</p>
                </div>
                <button onclick="window.close()" class="px-4 py-2 bg-gray-100 hover:bg-gray-200 rounded-lg transition-colors">
                    Close
                </button>
            </div>
            
            <!-- Threat Assessment -->
            <div class="bg-gradient-to-r from-yellow-50 to-yellow-100 rounded-xl p-6 mt-6">
                <div class="flex items-center justify-between">
                    <div>
                        <h3 class="text-lg font-semibold text-yellow-900">Threat Level: Moderate (#3) - IP Risk</h3>
                        <p class="text-yellow-700 mt-1">No clinical program but significant patent holdings</p>
                    </div>
                    <div class="text-4xl">⚠️</div>
                </div>
            </div>
        </div>
    </header>

    <!-- Navigation Tabs -->
    <nav class="bg-white border-b border-gray-200 sticky top-0 z-10">
        <div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8">
            <div class="flex space-x-8">
                <button onclick="showTab('overview')" class="tab-button active py-4 px-1 border-b-2 font-medium text-sm">
                    Overview
                </button>
                <button onclick="showTab('patents')" class="tab-button py-4 px-1 border-b-2 border-transparent font-medium text-sm text-gray-500 hover:text-gray-700">
                    Patent Portfolio
                </button>
                <button onclick="showTab('financial')" class="tab-button py-4 px-1 border-b-2 border-transparent font-medium text-sm text-gray-500 hover:text-gray-700">
                    Financial Data
                </button>
                <button onclick="showTab('safety')" class="tab-button py-4 px-1 border-b-2 border-transparent font-medium text-sm text-gray-500 hover:text-gray-700">
                    Safety Issues
                </button>
            </div>
        </div>
    </nav>

    <!-- Main Content -->
    <main class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8 py-8">
        <!-- Overview Tab -->
        <div id="overview" class="tab-content active">
            <div class="bg-white rounded-lg shadow-sm border border-gray-200 p-6 mb-6">
                <h2 class="text-xl font-semibold mb-4">Strategic IP Threat Assessment</h2>
                
                <div class="grid grid-cols-1 md:grid-cols-2 gap-6">
                    <div>
                        <h3 class="font-semibold text-gray-900 mb-3">Why They Matter</h3>
                        <ul class="space-y-2 text-sm text-gray-600">
                            <li class="flex items-start">
                                <span class="text-yellow-600 mr-2">✓</span>
                                <span>Holds granted patents covering exon 44 antisense sequences</span>
                            </li>
                            <li class="flex items-start">
                                <span class="text-yellow-600 mr-2">✓</span>
                                <span>Could assert IP against Avidity if AOC-1044 uses overlapping sequences</span>
                            </li>
                            <li class="flex items-start">
                                <span class="text-yellow-600 mr-2">✓</span>
                                <span>Potential licensing requirements or litigation risk</span>
                            </li>
                            <li class="flex items-start">
                                <span class="text-yellow-600 mr-2">✓</span>
                                <span>2 high-proximity patents (score 80-100)</span>
                            </li>
                        </ul>
                    </div>
                    
                    <div>
                        <h3 class="font-semibold text-gray-900 mb-3">Current Situation</h3>
                        <ul class="space-y-2 text-sm text-gray-600">
                            <li class="flex items-start">
                                <span class="text-red-600 mr-2">❌</span>
                                <span>No clinical program for exon 44</span>
                            </li>
                            <li class="flex items-start">
                                <span class="text-red-600 mr-2">❌</span>
                                <span>36% workforce reduction (500 layoffs)</span>
                            </li>
                            <li class="flex items-start">
                                <span class="text-red-600 mr-2">❌</span>
                                <span>Elevidys safety issues (multiple patient deaths)</span>
                            </li>
                            <li class="flex items-start">
                                <span class="text-red-600 mr-2">❌</span>
                                <span>FDA shipment halt, EMA rejection</span>
                            </li>
                        </ul>
                    </div>
                </div>

                <div class="mt-6 bg-blue-50 rounded-lg p-4">
                    <p class="text-sm text-blue-900">
                        <strong>Strategic Impact:</strong> Not a drug rival, but a legal/IP obstacle that could 
                        delay or encumber launch via licensing or litigation. Financial constraints may affect 
                        IP enforcement approach.
                    </p>
                </div>
            </div>

            <div class="bg-white rounded-lg shadow-sm border border-gray-200 p-6">
                <h3 class="font-semibold mb-3">Key Risk Metrics</h3>
                <div class="grid grid-cols-2 md:grid-cols-4 gap-4">
                    <div class="text-center p-4 bg-gray-50 rounded-lg">
                        <p class="text-2xl font-bold text-yellow-600">2</p>
                        <p class="text-xs text-gray-600">High Proximity Patents</p>
                    </div>
                    <div class="text-center p-4 bg-gray-50 rounded-lg">
                        <p class="text-2xl font-bold text-gray-600">No</p>
                        <p class="text-xs text-gray-600">Clinical Program</p>
                    </div>
                    <div class="text-center p-4 bg-gray-50 rounded-lg">
                        <p class="text-2xl font-bold text-red-600">36%</p>
                        <p class="text-xs text-gray-600">Workforce Reduction</p>
                    </div>
                    <div class="text-center p-4 bg-gray-50 rounded-lg">
                        <p class="text-2xl font-bold text-green-600">$638.2M</p>
                        <p class="text-xs text-gray-600">2024 Revenue</p>
                    </div>
                </div>
            </div>
        </div>

        <!-- Patents Tab -->
        <div id="patents" class="tab-content">
            <div class="bg-white rounded-lg shadow-sm border border-gray-200 p-6 mb-6">
                <h2 class="text-xl font-semibold mb-4">Exon 44 Patent Portfolio</h2>
                
                <div class="mb-6">
                    <h3 class="font-semibold text-red-900 mb-3">High Proximity Patents (Score: 80-100)</h3>
                    <div class="space-y-3">
                        <div class="bg-red-50 border border-red-200 rounded-lg p-4">
                            <div class="flex items-start justify-between">
                                <div>
                                    <h4 class="font-medium text-red-900">US10907154B2</h4>
                                    <p class="text-sm text-gray-600 mt-1">PMO (SEQ ID NO: 6) for exon 44 skipping in DMD</p>
                                    <p class="text-sm text-gray-600">Covers PEGylation and IV delivery</p>
                                    <p class="text-xs text-gray-500 mt-2">Expiry: ~2037</p>
                                </div>
                                <span class="px-2 py-1 bg-red-100 text-red-700 rounded-full text-xs font-semibold">Score: 95</span>
                            </div>
                        </div>
                        
                        <div class="bg-red-50 border border-red-200 rounded-lg p-4">
                            <div class="flex items-start justify-between">
                                <div>
                                    <h4 class="font-medium text-red-900">US9217148B2</h4>
                                    <p class="text-sm text-gray-600 mt-1">Claims 28-base PMO for exon 44 skipping</p>
                                    <p class="text-sm text-gray-600">Includes delivery-enhancing conjugates</p>
                                    <p class="text-xs text-gray-500 mt-2">Expiry: ~2033</p>
                                </div>
                                <span class="px-2 py-1 bg-red-100 text-red-700 rounded-full text-xs font-semibold">Score: 90</span>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="mb-6">
                    <h3 class="font-semibold text-orange-900 mb-3">Medium Proximity Patents (Score: 30-60)</h3>
                    <div class="space-y-3">
                        <div class="bg-orange-50 border border-orange-200 rounded-lg p-4">
                            <h4 class="font-medium text-orange-900">US9469664B2, US10202602B2</h4>
                            <p class="text-sm text-gray-600 mt-1">Oligonucleotide analogues targeting DMD</p>
                        </div>
                        <div class="bg-orange-50 border border-orange-200 rounded-lg p-4">
                            <h4 class="font-medium text-orange-900">US10888578B2</h4>
                            <p class="text-sm text-gray-600 mt-1">Exon skipping oligomer conjugates for muscular dystrophy</p>
                        </div>
                    </div>
                </div>

                <div class="bg-yellow-50 rounded-lg p-6">
                    <h3 class="font-semibold text-yellow-900 mb-3">IP Risk Mitigation Strategies</h3>
                    <ul class="space-y-2 text-sm">
                        <li>• Design around existing claims with novel sequences</li>
                        <li>• Pursue licensing agreement proactively</li>
                        <li>• Challenge patent validity if necessary</li>
                        <li>• Leverage Sarepta's current financial constraints</li>
                    </ul>
                </div>
            </div>
        </div>

        <!-- Financial Tab -->
        <div id="financial" class="tab-content">
            <div class="bg-white rounded-lg shadow-sm border border-gray-200 p-6 mb-6">
                <h2 class="text-xl font-semibold mb-4">Financial Performance & Restructuring</h2>
                
                <div class="grid grid-cols-1 md:grid-cols-2 gap-6 mb-6">
                    <div class="bg-green-50 rounded-lg p-6">
                        <h3 class="font-semibold text-green-900 mb-3">2024 Financial Results</h3>
                        <div class="space-y-2">
                            <div class="flex justify-between">
                                <span class="text-sm">Net Product Revenue:</span>
                                <span class="font-semibold">$638.2M (+75% YoY)</span>
                            </div>
                            <div class="flex justify-between">
                                <span class="text-sm">GAAP Profit:</span>
                                <span class="font-semibold">$159M</span>
                            </div>
                            <div class="flex justify-between">
                                <span class="text-sm">Non-GAAP Profit:</span>
                                <span class="font-semibold">$206M</span>
                            </div>
                        </div>
                    </div>
                    
                    <div class="bg-red-50 rounded-lg p-6">
                        <h3 class="font-semibold text-red-900 mb-3">Cost-Cutting Measures</h3>
                        <div class="space-y-2">
                            <div class="flex justify-between">
                                <span class="text-sm">Workforce Reduction:</span>
                                <span class="font-semibold">~36% (500 layoffs)</span>
                            </div>
                            <div class="flex justify-between">
                                <span class="text-sm">Annual Savings Target:</span>
                                <span class="font-semibold">$400M</span>
                            </div>
                            <div class="flex justify-between">
                                <span class="text-sm">Cash Position:</span>
                                <span class="font-semibold">~$850M</span>
                            </div>
                        </div>
                    </div>
                </div>

                <h3 class="font-semibold mb-3">Quarterly Revenue Trend</h3>
                <div class="overflow-x-auto">
                    <table class="w-full text-sm">
                        <thead>
                            <tr class="border-b">
                                <th class="text-left py-2">Period</th>
                                <th class="text-right py-2">Net Product Revenue</th>
                                <th class="text-right py-2">YoY Growth</th>
                                <th class="text-left py-2">Key Development</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr class="border-b">
                                <td class="py-2">Q2 2024</td>
                                <td class="text-right">$360.5M</td>
                                <td class="text-right text-green-600">+51%</td>
                                <td>ELEVIDYS launch ramp</td>
                            </tr>
                            <tr class="border-b">
                                <td class="py-2">Q3 2024</td>
                                <td class="text-right">$429.8M</td>
                                <td class="text-right text-green-600">+39%</td>
                                <td>Strong DMD portfolio sales</td>
                            </tr>
                            <tr class="border-b bg-yellow-50">
                                <td class="py-2 font-semibold">Q4/FY 2024</td>
                                <td class="text-right font-semibold">$638.2M</td>
                                <td class="text-right font-semibold text-green-600">+75%</td>
                                <td>$600M credit facility launched</td>
                            </tr>
                            <tr class="border-b">
                                <td class="py-2">Mid-2025</td>
                                <td class="text-right">$282M (Q2 Elevidys)</td>
                                <td class="text-right text-red-600">Missed expectations</td>
                                <td>Safety concerns emerge</td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <div class="mt-6 bg-gray-100 rounded-lg p-4">
                    <p class="text-sm text-gray-700">
                        <strong>Financial Impact:</strong> Despite strong 2024 revenue growth, 2025 challenges including 
                        safety issues and workforce reduction indicate financial pressure that may affect IP enforcement strategy.
                    </p>
                </div>
            </div>
        </div>

        <!-- Safety Tab -->
        <div id="safety" class="tab-content">
            <div class="bg-white rounded-lg shadow-sm border border-gray-200 p-6 mb-6">
                <h2 class="text-xl font-semibold mb-4">Elevidys Safety Crisis</h2>
                
                <div class="bg-red-50 border border-red-200 rounded-lg p-6 mb-6">
                    <h3 class="font-semibold text-red-900 mb-3">⚠️ Critical Safety Issues</h3>
                    <div class="space-y-4">
                        <div>
                            <p class="font-medium">Multiple Patient Deaths</p>
                            <p class="text-sm text-gray-600 mt-1">FDA ordered halt to Elevidys shipments due to acute liver failure deaths</p>
                        </div>
                        <div>
                            <p class="font-medium">European Rejection</p>
                            <p class="text-sm text-gray-600 mt-1">EMA denied approval citing insufficient efficacy and safety concerns</p>
                        </div>
                        <div>
                            <p class="font-medium">Regulatory Trust Damaged</p>
                            <p class="text-sm text-gray-600 mt-1">Initial resistance to FDA pause harmed regulatory relationships</p>
                        </div>
                        <div>
                            <p class="font-medium">Suspended Gene Therapy Expansion</p>
                            <p class="text-sm text-gray-600 mt-1">Other gene therapy programs halted due to safety concerns</p>
                        </div>
                    </div>
                </div>

                <div class="bg-yellow-50 rounded-lg p-6 mb-6">
                    <h3 class="font-semibold text-yellow-900 mb-3">Commercial Impact</h3>
                    <div class="space-y-2">
                        <p class="text-sm">• ~$820M Elevidys revenue in first full year</p>
                        <p class="text-sm">• Mid-2025: FDA ordered shipment halt</p>
                        <p class="text-sm">• Q2 Elevidys revenue: ~$282M (missed expectations)</p>
                        <p class="text-sm">• 2027 debt obligations pending</p>
                    </div>
                </div>

                <div class="mt-6 bg-gray-100 rounded-lg p-4">
                    <p class="text-sm text-gray-700">
                        <strong>Strategic Impact:</strong> These safety challenges may impact Sarepta's strategic focus 
                        and resource allocation, potentially affecting their approach to IP enforcement in the exon 
                        skipping space.
                    </p>
                </div>
            </div>
        </div>
    </main>

    <!-- Footer -->
    <footer class="bg-gray-100 py-4 mt-12">
        <div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8">
            <p class="text-xs text-gray-600 text-center">
                Last updated: July 28, 2025 | Data sources: Investors.com, Wall Street Journal, Washington Post, BioSpace, SEC filings
            </p>
        </div>
    </footer>

    <script>
        // Tab functionality
        function showTab(tabName) {
            // Hide all tabs
            document.querySelectorAll('.tab-content').forEach(tab => {
                tab.classList.remove('active');
            });
            
            // Remove active class from all buttons
            document.querySelectorAll('.tab-button').forEach(button => {
                button.classList.remove('active', 'text-indigo-600', 'border-indigo-500');
                button.classList.add('text-gray-500', 'border-transparent');
            });
            
            // Show selected tab
            document.getElementById(tabName).classList.add('active');
            
            // Set active button
            event.target.classList.remove('text-gray-500', 'border-transparent');
            event.target.classList.add('active', 'text-indigo-600', 'border-indigo-500');
        }
    </script>
</body>
</html>